These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24139794)

  • 21. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.
    Endy TP; Nisalak A; Chunsuttitwat S; Vaughn DW; Green S; Ennis FA; Rothman AL; Libraty DH
    J Infect Dis; 2004 Mar; 189(6):990-1000. PubMed ID: 14999601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.
    Gil L; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Marcos E; Suzarte E; Kariuki T; Guzmán G; Guillén G; Hermida L
    Virology; 2014 May; 456-457():70-6. PubMed ID: 24889226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.
    Valdés I; Hermida L; Gil L; Lazo L; Castro J; Martín J; Bernardo L; López C; Niebla O; Menéndez T; Romero Y; Sánchez J; Guzmán MG; Guillén G
    Int J Infect Dis; 2010 May; 14(5):e377-83. PubMed ID: 19773190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques.
    McCracken MK; Gromowski GD; Garver LS; Goupil BA; Walker KD; Friberg H; Currier JR; Rutvisuttinunt W; Hinton KL; Christofferson RC; Mores CN; Vanloubbeeck Y; Lorin C; Malice MP; Thomas SJ; Jarman RG; Vaughn DW; Putnak JR; Warter L
    PLoS Negl Trop Dis; 2020 Apr; 14(4):e0008191. PubMed ID: 32267846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
    Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
    Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of dengue: an update.
    Tang KF; Ooi EE
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):895-907. PubMed ID: 23030329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.
    Maves RC; Oré RM; Porter KR; Kochel TJ
    Vaccine; 2011 Mar; 29(15):2691-6. PubMed ID: 21303709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
    Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
    Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus.
    Ito M; Mukai RZ; Takasaki T; Kotaki A; Kurane I
    Arch Virol; 2010 Oct; 155(10):1617-24. PubMed ID: 20644969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
    Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
    BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
    Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey.
    Hanley KA; Guerbois M; Kautz TF; Brown M; Whitehead SS; Weaver SC; Vasilakis N; Marx PA
    Am J Trop Med Hyg; 2014 Oct; 91(4):672-6. PubMed ID: 25092823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.
    Setthapramote C; Sasaki T; Puiprom O; Limkittikul K; Pitaksajjakul P; Pipattanaboon C; Sasayama M; Leuangwutiwong P; Phumratanaprapin W; Chamnachanan S; Kusolsuk T; Jittmittraphap A; Asai A; Arias JF; Hirai I; Kuhara M; Okuno Y; Kurosu T; Ramasoota P; Ikuta K
    Biochem Biophys Res Commun; 2012 Jul; 423(4):867-72. PubMed ID: 22713454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flow cytometry-based assay for titrating dengue virus.
    Lambeth CR; White LJ; Johnston RE; de Silva AM
    J Clin Microbiol; 2005 Jul; 43(7):3267-72. PubMed ID: 16000446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant envelope protein-based enzyme immunoassay for IgG antibodies is comparable to neutralization tests for epidemiological studies of dengue infection.
    Rocha ES; Oliveira JG; Santos JR; Rodrigues GO; Figueiredo LB; Pessanha JE; Proietti FA; Fonseca FG; Bonjardim CA; Ferreira PC; Kroon EG
    J Virol Methods; 2013 Jan; 187(1):114-20. PubMed ID: 23018061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.
    Vaughn DW; Green S; Kalayanarooj S; Innis BL; Nimmannitya S; Suntayakorn S; Endy TP; Raengsakulrach B; Rothman AL; Ennis FA; Nisalak A
    J Infect Dis; 2000 Jan; 181(1):2-9. PubMed ID: 10608744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamics of cellular immune responses in the acute phase of dengue virus infection.
    Yoshida T; Omatsu T; Saito A; Katakai Y; Iwasaki Y; Kurosawa T; Hamano M; Higashino A; Nakamura S; Takasaki T; Yasutomi Y; Kurane I; Akari H
    Arch Virol; 2013 Jun; 158(6):1209-20. PubMed ID: 23381396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.